

Rec'd PCT/PTO 17 DEC 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re International patent application of

Enzo Therapeutics, Inc.

Jayanta Roy-Chowdhury, et al.

International Application No. PCT/US/98/03606

International Filing Date: February 26, 1998

U.S. Application No.: 09/171,909

**COPY**

527 Madison Avenue, 9th Floor  
New York, New York 10022  
December 16, 2002

**FILED BY HAND**

Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20233  
**Attention: Box PCT**

**REQUEST FOR AN EXTENSION FOR RESPONSE**  
**WITHIN THE FIRST MONTH UNDER 37 CFR §1.17(a)(1)**  
**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE**

Dear Sirs:

Applicants hereby request a three-month extension of time for responding to the Notification Of Missing Requirements Under 35 U.S.C. 371 In The United States Designated /Elected Office mailed on September 17, 2002. The Patent and Trademark office is hereby authorized to charge Deposit Account No. 05-1135 for the requisite fee of \$55.00 for an extension for response within the first month for a small entity as set forth in 37 C.F.R. §1.17(3).

No other fee is believed due in connection with this extension request. If any other fee or fees are due, however, authorization is hereby made to charge the amount

**Attorney Docket: ENZ-55(CIP)(PCT)(US)**

In re International Patent Application of  
Enzo Therapeutics, Inc.

Jayanta Roy-Chowdhury, et al.

International Application No. PCT/US/98/03606


International Filing Date: February 26, 1998

U.S. Application No. 09/171,909

Page 2 (Request For An Extension For Response within The First Month  
Under 37 CFR § 1/17(a)(1)- December 16, 2002

of any such other fee(s) to Deposit Account No. 05-1135 or to charge any overpayment  
thereto. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10017  
Tel.: (212) 583-0100  
Fax.: (212) 583-0150

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re International patent application of

Enzo Therapeutics, Inc.

Jayanta Roy-Chowdhury, et al.

International Application No. PCT/US/98/03606

International Filing Date: February 26, 1998

U.S. Application No.: 09/171,909

527 Madison Avenue, 9th Floor  
New York, New York 10022  
December 16, 2002

**FILED BY HAND**

Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20233  
**Attention: Box PCT**

**REQUEST FOR AN EXTENSION FOR RESPONSE**  
**WITHIN THE FIRST MONTH UNDER 37 CFR §1.17(a)(1)**  
**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE**

Dear Sirs:

Applicants hereby request a three-month extension of time for responding to the Notification Of Missing Requirements Under 35 U.S.C. 371 In The United States Designated /Elected Office mailed on September 17, 2002. The Patent and Trademark office is hereby authorized to charge Deposit Account No. 05-1135 for the requisite fee of \$55.00 for an extension for response within the first month for a small entity as set forth in 37 C.F.R. §1.17(3).

No other fee is believed due in connection with this extension request. If any other fee or fees are due, however, authorization is hereby made to charge the amount

**Attorney Docket: ENZ-55(CIP)(PCT)(US)**

In re International Patent Application of  
Enzo Therapeutics, Inc.

Jayanta Roy-Chowdhury, et al.


International Application No. PCT/US/98/03606

International Filing Date: February 26, 1998

U.S. Application No. 09/171,909

Page 2 (Request For An Extension For Response within The First Month  
Under 37 CFR § 1/17(a)(1)- December 16, 2002

of any such other fee(s) to Deposit Account No. 05-1135 or to charge any overpayment  
thereto. A duplicate copy of this sheet is enclosed.

Respectfully submitted,  
  
Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10017  
Tel.: (212) 583-0100  
Fax.: (212) 583-0150

**Attorney Docket: ENZ-55(CIP)(PCT)(US)**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re International patent application of

Enzo Therapeutics, Inc.

Jayanta Roy-Chowdhury, et al.

International Application No. PCT/US/98/03606

International Filing Date: February 26, 1998

U.S. Application No.: 09/171,909

527 Madison Avenue, 9th Floor  
New York, New York 10022  
December 16, 2002

**FILED BY HAND**

Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20233  
**Attention: Box PCT**

**COMMUNICATION IN CONNECTION WITH**  
**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371**  
**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE – SEQUENCE RULES**

Dear Sirs:

Applicants are submitting this Communication in connection with the Notification Of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) requiring compliance with sequence rules that was issued on September 17, 2002. A response to the September 17, 2002 Notification was due on November 17, 2002. Prior to the November 17, 2002 due date the undersigned applicants' attorney telephonically requested an extension of time in which to respond to the Notification from Examiner Patricia A. Booker. Examiner Booker granted applicants' attorneys' request. Accordingly, with the submission of the below referenced items, a response to the Notification Of Missing Requirements is being timely filed.

**Attorney Docket: ENZ-55(CIP)(PCT)(US)**

In re International Patent Application of  
Enzo Therapeutics Inc.

Jayanta Roy-Chowdhury, et al.

International Application No. PCT/US/98/03606

International Filing Date: February 26, 1998

U.S. Application No. 09/171,909


Page 2 (Communication In Connection With Notification Of Missing Requirements  
Under 35 U.S.C. 371 In the DO/Eo/US – Sequence Rules)  
– December 16, 2002)

By this Communication, applicants are submitting a copy of the requested Sequence Listing in computer readable pursuant to the provisions of 37 C.F.R. § 1.821(e), a paper copy of the sequence listing, a Statement Accompanying Sequence Listing, and a Request For An Extension For Response Within The First Month Under 37 CFR §1.17(a)(1).

No fee is believed due in connection with this Communication and its enclosures with the exception of the \$55.00 fee for filing the Extension request for a small entity. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication and its enclosures, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

**Attorney Docket: ENZ-55(CIP)(PCT)(US)**



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

| U.S. APPLICATION NUMBER NO. | FIRST NAMED APPLICANT | ATTY. DOCKET NO. |
|-----------------------------|-----------------------|------------------|
| 09/171,909                  | Jayanta Roy-Chowdhury | ENZ-55(CIP)PC    |

| INTERNATIONAL APPLICATION NO. |
|-------------------------------|
|-------------------------------|

PCT/US98/03606

| I.A. FILING DATE | PRIORITY DATE |
|------------------|---------------|
|------------------|---------------|

02/26/1998

02/28/1997

Enzo Therapeutics Inc.  
Enzo Biochem Inc  
9th Floor  
527 Madison Avenue  
New York, NY 10022

CONFIRMATION NO. 8638

371 FORMALITIES LETTER



\*OC000000008792826\*

Date Mailed: 09/17/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Claims
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PATRICIA A BOOKER

Telephone: (703) 305-3738

**PART 1 - ATTORNEY/APPLICANT COPY**

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
| 09/171,909                  | PCT/US98/03606                | ENZ-55(CIP)PC    |

FORM PCT/DO/EO/905 (371 Formalities Notice)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: ENZ-55 (CIP) (PCT) (US)

In re International patent application of

ENZO THERAPEUTICS, INC.

International Application No. PCT/US98/03606

International Filing Date: February 26, 1998

For: NOVEL PROCESSES IMPLEMENTING SELECTIVE IMMUNE DOWN REGULATION (SIDR)

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box PCT SEQUENCE


STATEMENT ACCOMPANYING SEQUENCE LISTING

Dear Sir:

The undersigned hereby states that the Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing.

Respectfully submitted,

Dec. 9, 2002  
Date

  
James A. Coburn

HARBOR CONSULTING  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021

## SEQUENCE LISTING

<110> ENZO THERAPEUTICS, INC.

<120> NOVEL PROCESSES IMPLEMENTING SELECTIVE IMMUNE  
DOWN REGULATION (SIDR)

<130> ENZ-55 (CIP) (PCT) (US)

<140> PCT/US98/03606

<141> 1998-02-26

<150> 09/171,909

<151> 1997-02-28

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> DNA

<213> Homo sapiens

<400> 1

aaggaaaggg tccgtcagca

20

<210> 2

<211> 19

<212> DNA

<213> Homo sapiens

<400> 2

ccagcagctg cagcagagg

19